leadf
logo-loader
RNS
viewIntelligent Ultrasound Group PLC

Intelligent Ultrasnd - Trading Update

RNS Number : 7355S
Intelligent Ultrasound Group PLC
13 July 2020
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Group")

 

Trading Update

 

Intelligent Ultrasound Group plc (AIM: MED), the artificial intelligence (AI) based ultrasound software and simulation company, announces that Group turnover for the six months to 30 June 2020, which is currently generated entirely by the Group's Simulation Division, is expected to be £2.5m (H1 2019: £3.1m). The shortfall is due to the effect of COVID-19 on the Group's reseller sales, especially in the Chinese and European markets, which declined to £0.6m (H1 2019: £1.4m). The Group's direct sales in the period grew by 4% to £1.9m (H1 2019: £1.8m) despite COVID-19 impacting US revenues.

 

The global COVID-19 lockdown, which has affected the majority of the reporting period, has dramatically constrained the Group's ability to demonstrate and therefore sell ultrasound training simulators to hospitals around the world. However, the directors are encouraged that despite these restrictions, the Group has increased sales in the UK, limited the sales shortfall overseas and successfully managed Group expenses to limit the adjusted EBITDA loss for the period to be between £1.3m-£1.4m (H1 2019: loss of £1.3m).

 

The Group continues to work flat out to bring its range of AI-based clinical software products to market and the Group remains on target to achieve its first AI related revenues in 2021, as originally planned, even though the pandemic has restricted some access to doctors and trial patients and has delayed delivery of some new hardware components.

 

Discussions with a number of OEMs for the Group's second ScanNav AI software agreement continue and submission of AnatomyGuide's first regulatory filing is expected this summer.

 

In May the Company undertook a successful placing, raising £4.8m net of costs and as such cash at 30 June 2020 was £10.1m (31 December 2019: £7.3m). Despite all the COVID-19 related restrictions that the Group is currently working under, management remain confident that this cash position, combined with a growing ultrasound simulator product range and a stream of anticipated future Clinical AI software revenues, should enable the Group to reach its profitability inflection point.

 

Stuart Gall, CEO of Intelligent Ultrasound Group plc, commented:

 

"The team has responded brilliantly to the COVID-19 restrictions. Working from home our direct sales team have found ways of continuing to sell our ultrasound training simulators to hospitals and our AI software development teams have continued to meet all our internal development milestones for the Group's new AI-based image analysis software. Some elements have been outside our control however and access to doctors and trial patients has inevitably caused some delay. Despite this we currently remain on target for first AI revenues in 2021, as planned.

 

"We are particularly proud to have produced a COVID-19 training module in record time and, by offering the module free to our customers, were able to play a significant role in training frontline staff, especially in London (Nightingale Hospital) and New York (VA Harbor Healthcare), in the fight against the virus."

 

Enquiries:

 

Intelligent Ultrasound Group plc

www.intelligentultrasound.com

Stuart Gall, CEO
Helen Jones, CFO

Tel: +44 (0)29 2075 6534



Cenkos Securities plc

Tel:  +44 (0)20 7397 8900

Giles Balleny/Cameron MacRitchie (Nominated Adviser)


Michael Johnson/Julian Morse (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780  or [email protected]

Anna Dunphy/Paul McManus

Mob: +44 (0)7876 741 001 / +44 (0)7980 541 893

 

About Intelligent Ultrasound Group www.intelligentultrasound.com

 

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.


Based in Cardiff in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:


Clinical AI Division

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and  AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

 

Simulation Division

Focusses on hi-fidelity ultrasound education and training through simulation.  Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 850 simulators have been sold to over 500 medical institutions around the world.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTFLFETDVIFLII

Quick facts: Intelligent Ultrasound Group PLC

Price: 15.25

Market: AIM
Market Cap: £41.08 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read